MIEBO (perfluorohexyloctane)

Self-Administration – ophthalmic solution

Diagnosis considered for coverage:
  • Dry Eye Disease: Indicated for the treatment of the signs and symptoms of dry eye disease.
Coverage Criteria:

For diagnosis of dry eye disease:

  • Diagnosis of dry eye disease confirmed by ONE of the following diagnostic tests: 
    • Schirmer test 
    • Ocular surface dye staining (e.g., rose bengal, fluorescein, lissamine green) 
    • Tear function index/fluorescein clearance test 
    • Tear break up time 
    • Tear film osmolarity 
    • Slit lamp lid evaluation 
    • Lacrimal gland function; AND
  • Patient is 18 years of age or older; AND
  • Prescribed by or in consultation with an ophthalmologist or optometrist; AND
  • Trial and failure, contraindication, or intolerance to at least one OTC ocular lubricant (e.g., artificial tears, lubricating gels/ointments); AND
  • Trial and failure, contraindication, or intolerance to both of the following: 
    • Restasis (cyclosporine 0.05%) 
    • Xiidra (lifitegrast)
Reauthorization Criteria:

For diagnosis of dry eye disease:

  • Documentation of positive clinical response to therapy (e.g., increased tear production or improvement in dry eye symptoms)
Coverage Duration: 
  • Initial: 3 months
  • Reauthorization: 12 months
Dosing:
  • MIEBO is administered as one drop four times daily into the affected eye(s).
  • Contact lenses should be removed prior to and for at least 30 minutes after administration of MIEBO
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information: 
  • The safety and effectiveness of MIEBO in pediatric patients below the age of 18 years have not been established.
  • Traditional diagnostic tests include the Schirmer test, ocular surface dye staining, tear function index/fluorescein clearance test, tear break up time, tear film osmolarity, slit lamp evaluation of lid.
  • As disease severity increases, aqueous enhancement of the eye using topical agents is appropriate (e.g., emulsions, gels, ointments). Anti-inflammatory therapies (e.g., topical cyclosporine, corticosteroids), systemic omega-3 fatty acid supplements, punctal plugs, and eyeglass side shields/moisture chambers may also be considered in addition to aqueous enhancement therapies in patients who need additional symptom management.
Policy Updates:
  • 03/01/2024 – New policy for Miebo approved by WHA P&T Committee. (P&T, 02/20/2024)
References:
  1. Miebo Prescribing Information. Bausch & Lomb Americas Inc. Bridgewater, NJ. May 2023. 
  2. American Academy of Ophthalmology. Dry Eye Syndrome Preferred Practice Pattern. October 2018. Available at file:///C:/Users/kdekhtaw/OneDrive%20-%20UHG/Homedir/2020%20CLIENT%20LISTS/UTILIZATION%20MANAGEMENT/M/MIEBO/Dry%20Eye%20Syndrome%20Preferred%20Practice%20Pattern%202018.pdf. Accessed July 11, 2023. 
  3. Wood, S., Mian, S. Diagnostic Tools for Dry Eye Disease. Available at https://www.touchophthalmology.com/wp-content/uploads/sites/16/2017/01/Diagnostic-Tools-for-Dry-Eye-Disease_1.pdf. Accessed Nov 9. 2021. 
  4. Zeev, M., Miller, D, et al. Diagnosis of dry eye disease and emerging technologies. Clin Ophthalmol 2014;8:581-590. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3964175/#b16-opth-8-581. Accessed November 9, 2021. 
  5. Tauber, J., Berdy, G., et al. NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study. American Academy of Ophthalmology. Dec 2022: 516-524. Available at:https://www.aaojournal.org/article/S0161-6420(22)01016-8/pdf#:~:text=NOV03%2C%20a%20novel%2C%20nonaqueous%2C%20single-entity%2C%20preservative-%20free%2C%20ophthalmic,glands%20through%2024%20hours%2C%20with%20minimal%20systemic%20exposure.26. Accessed July 11, 2023. 
  6. Sheppard,J., Kurata, F., et al. NOV03 for Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction: The Randomized Phase 3 MOJAVE Study. American Journal of Ophthalmology. Mar 2023: 265-274. Available at: https://www.ajo.com/action/showPdf?pii=S0002-9394%2823%2900098-3. Accessed July 11, 2023. 

Last review date: March 1, 2024

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone